Akari Therapeutics (AKTX) Convertible Debt (2024 - 2026)

Akari Therapeutics (AKTX) has reported Convertible Debt for 3 consecutive years, with $683000.0 the latest figure, recorded in Q1 2026.

• Quarterly Convertible Debt fell 2.43% year-over-year to $683000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $683000.0 (down 2.43% YoY) and the FY2025 annual result came in at $673000.0, down 3.86% from the prior year.
• Convertible Debt grew to $683000.0 in Q1 2026 per AKTX's latest filing, from $673000.0 in the prior quarter.
• Over the last five years, Convertible Debt for AKTX reached as high as $700000.0 in Q4 2024 and fell as low as $663000.0 in Q3 2025.
• A 3-year average of $686500.0 and a median of $691500.0 in 2024 frame the typical range for Convertible Debt.
• Annual changes were most pronounced in 2025 — Convertible Debt decreased 3.86% — and 2026, when it dropped 2.43%.
• Year by year, Convertible Debt stood at $700000.0 in 2024, then fell by 3.86% to $673000.0 in 2025, then gained by 1.49% to $683000.0 in 2026.
• According to Business Quant data, Convertible Debt over the past three periods registered $683000.0, $673000.0, and $663000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.